Effect of atomoxetine on executive function impairments in adults with ADHD

Journal of Attention Disorders

Volumn 15, Issue 2, 2011, Pages 130-138

  Brown, Thomas E ^a   Holdnack, James ^b   Saylor, Keith ^c   Adler, Lenard ^d   Spencer, Thomas ^e   Williams, David W ^f   Padival, Anoop K ^f   Schuh, Kory ^f   Trzepacz, Paula T ^g,h,i,j   Kelsey, Douglas ^f  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychological Corporation   (United States)

^c NeuroScience Inc   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f Lilly USA   (United States)

^g ELI LILLY AND COMPANY   (United States)

^h UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

ADHD; adults; atomoxetine; Brown ADD Scale for Adults; executive functioning

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; ATOMOXETINE; PROPYLAMINE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXECUTIVE FUNCTION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPYLAMINES; TREATMENT OUTCOME;

EID: 79551636981     PISSN: 10870547     EISSN: 15571246     Source Type: Journal    
DOI: 10.1177/1087054709356165     Document Type: Article

References (36)

1. Adler, L., & Cohen, J. (2004). Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatric clinics of North America, 27, 187-201.
2. Adler, L., Dietrich, A., Reimherr, F.W., Taylor, L.V.M., Sutton, V.K., Bakken, R.,et al.(2006). Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Annals of Clinical Psychiatry, 18, 107-113.
3. Adler, L.A., Liebowitz, M., Kronenberger, W., Qiao, M., Rubin, R., Hollandbeck, M.,et al.(2009a). Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety, 26, 212-221.
4. Adler, L., Spencer, T., Brown, T.E., Holdnack, J., Saylor, K., Schuh, K.,et al.(2009b). Once-daily atomoxetine for adult ADHD: A six-month double-blind trial. Journal of Clinical Psychopharmacology, 29, 44-50.
5. Allen, A.J., Kurlan, R.M., Gilbert, D.L., Coffey, B.J., Linder, S.L., Lewis, D.W.,et al.(2005). Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology, 65, 1941-1949.
6. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text revision). Washington, DC: American Psychiatric Association.
7. Barkley, R.A. (1997). Behavioral inhibition, sustained attention, and executive functions: Constructing a unifying theory of ADHD. Psychological Bulletin, 121, 65-94.
8. Barkley, R.A., Murphy, K.R., & Fischer, M. (2008). ADHD in adults: What the science says. New York: Guilford.
9. Biederman, J., Petty, C.R., Doyle, A.E., Spencer, T., Henderson, C.S.,et al.(2008a). Stability of executive function deficits in girls with ADHD: A prospective longitudinal followup study into adolescence. Developmental Neuropsychology, 33, 44-61.
10. Biederman, J., Petty, C.R., Fried, R., Doyle, A.E., Mick, E., Aleardi, M.,et al.(2008b). Utility of an abbreviated questionnaire to identify individuals with ADHD at risk for functional impairments. Journal of Psychiatric Research, 42, 304-310.
11. Biederman, J., Petty, C.R., Fried, R., Doyle, A.E., Spencer, T.et al.(2007a). Stability of executive function deficits into young adult years: A prospective longitudinal follow-up study of grown up males with ADHD. Acta Psychiatrica Scandinavica, 116, 129-136.
12. Biederman, J., Petty, C., Fried, R., Fontanella, J., Doyle, A.E., Seidman, L.J.,et al.(2006). Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. American Journal of Psychiatry, 163, 1730-1738.
13. Biederman, J., Petty, C.R., Fried, R., Fontanella, J., Doyle, A.E., Seidman, L.J.,et al.(2007b). Can self-reported behavioral scales assess executive function deficits? A controlled study of adults with ADHD. Journal of Nervous and Mental Disease, 195, 240-246.
14. Brown, T.E. (1996). Brown ADD scales manual for adolescents and adults. San Antonio, TX: Psychological Corporation.
15. Brown, T.E. (2000). Emerging understanding of attention-deficit disorders and comorbidities. In T. E. Brown (Ed.), Attention deficit disorders and comorbidities in children, adolescents, and adults (pp. 3-56). Washington, DC: American Psychiatric Press.
16. Brown, T.E. (2005). Attention deficit disorder: The unfocused mind in children and adults. New Haven, CT: Yale University Press.
17. Brown, T.E. (2006). Executive functions and attention deficit hyperactivity disorder: Implications of two conflicting views. International Journal of Disability, Development, and Education, 53, 35-46.
18. Brown, T.E., & Quinlan, D. (2004, October). Assessing OROS methylphenidate effects on executive functions in adults with ADHD. Poster session presented at the Institute on Psychiatric Services Annual Meeting, Atlanta, GA.
19. Brown, T.E., Sutton, V.K., Rogers, A.K., & Sumner, C. (2005, May). Atomoxetine alleviates executive function impairment associated with ADHD. Poster session presented at the American Psychiatric Association Annual Meeting, Atlanta, GA.
20. Burgess, P.W. (1997). Theory and methodology in executive function research. In P. Rabbitt (Ed.), Methodology of frontal and executive function (pp. 81-116), East Sussex, England: Psychology Press.
21. Geller, D., Donnelly, C., Lopez, F., Rubin, R., Newcorn, J., Sutton, V.et al.(2007). Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1119-1127.
22. Guy, W. (1976). ECDEU assessment manual for psychopharmacology (Revised). Bethesda, MD: U.S. Department of Health, Education and Welfare.
23. Hinshaw, S.P., Carte, E.T., Fan, C., Jassy, J.S., & Owens, E.B. (2007). Neuropsychological functioning of girls with attention-deficit/hyperactivity disorder followed prospectively into adolescence: Evidence for continuing deficits? Neuropsychology, 21, 263-273.
24. Kelsey, D.K., Sumner, C.R., Casat, C.D., Coury, D.L., Quintana, H., Saylor, K.E.,et al.(2004). Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics, 114, e1.
25. Kooij, S.J.J., Boonstra, M.A., Swinkels, S.H., Bekker, E.M., de Noord, I., & Buitelaar, J.K. (2008). Reliability, validity and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. Journal of Attention Disorders, 11, 445-458.
26. Martel, M., Nikolas, M., & Nigg, J.T. (2007). Executive function in adolescents with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1437-1444.
27. Michelson, D., Adler, L., Spencer, T., Reimherr, F.W., West, S.A., Allen, A.J.,et al.(2003). Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biological Psychiatry, 53, 112-120.
28. Michelson, D., Allen, A.J., Busner, J., Casat, C., Dunn, D., Kratochvil, C.,et al.(2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. AmericanJournal of Psychiatry, 159, 1896-1901.
29. Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F.R.,et al.(2001). Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics, 108, e83.
30. Miyake, A., Friedman, N.P., Emerson, M.J., Witzki, A.H., Howerter, A., & Wager, T.D. (2000). The unity and diversity of executive functions and their contributions to complex frontal lobe tasks: A latent variable analysis. Cognitive Psychology, 41, 49-100.
31. Rabbitt, P. (1997). Methodologies and models in the study of executive function. In P. Rabbitt (Ed.), Methodology of frontal and executive function (pp. 1-38), East Sussex, England: Psychology Press.
32. Spencer, T.J., Adler, L.A., Weisler, R.H., & Youcha, S.H. (2008). Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: A randomized, double-blind, multicenter, placebo-controlled study. Journal of Clinical Psychiatry, 69, 1437-1448.
33. Spencer, T., Heiligenstein, J.H., Biederman, J., Faries, D.E., Kratochvil, C., Conners, C.K.,et al.(2002). Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 63, 1140-1147.
34. Stavro, G.M., Ettenhofer, M.L., & Nigg, J.T. (2007). Executive functions and adaptive functioning in young adult attention-deficit/hyperactivity disorder. Journal of the International Neuropsychological Society, 13, 324-334.
35. Vohs, K.D., & Baumeister, R.F. (2004). Understanding self-regulation: An introduction. In R. F. Baumeister & K. D. Vohs (Eds.), Handbook of self-regulation, research: Theory, and applications (pp. 1-13). New York: Guilford.
36. Wilens, T.E., Adler, L.A., Weiss, M.D., Michelson, D., Ramsey, J.L., Moore, R.J.,et al.(2008). Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug and Alcohol Dependence, 96, 145-154.